INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.
| PLYMOUTH MEETING, Pa., March 3, 2023 /PRNewswire/ -- Inovio Pharmaceuticals (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference. Oppenheimer 33rd Annual Healthcare Conference During the conference, Dr. Shea and members of INOVIO’s management team will conduct one-on-one meetings with registered investors. A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation. About INOVIO INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com. Contacts Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
SOURCE INOVIO Pharmaceuticals, Inc. | ||
Company Codes: NASDAQ-NMS:INO |
View original content:
